Adaptimmune Therapeutics Priced, Nasdaq: ADAP

Developing cancer immunotherapies using genetically enhanced T-cell receptors.

Industry: Health Care

Latest Trade: $4.29 +0.01 (+0.2%)

First Day Return: -5.9%

Return from IPO: -74.8%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on novel cancer immunotherapy products based on our T-cell receptor platform. We have developed a comprehensive proprietary platform that enables us to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer T-cell receptors and produce TCR therapeutic candidates for administration to patients. We engineer TCRs to increase their affinity to cancer-specific peptides, including our lead target peptides, NY-ESO and MAGE A-10, in order to target and then destroy cancer cells in patients. Unlike current antibodies and therapies that are based on the use of chimeric antigen receptor T cells, our TCR therapeutic candidates are able to target intracellular as well as extracellular cancer antigens. This capability significantly increases the breadth of targets, particularly as intracellular targets are known to be more closely associated with cancer but are inaccessible with other autologous T-cell immunotherapy approaches. We believe this approach will lead to TCR therapeutic candidates that have the potential to significantly impact cancer treatment and clinical outcomes of patients with cancer.
more less
IPO News for Adaptimmune Therapeutics
more
IPO Data
IPO File Date 04/06/2015
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 11.3
Deal Size ($mm) $191
IPO Data
IPO Date 05/05/2015
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 11.3
Deal Size ($mm) $191
Underwriters
more
Company Data
Headquarters Abingdon, United Kingdom
Founded 2008
Employees 106
Website www.adaptimmune.com